Related Experiment Video

Updated: Mar 30, 2026

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds
09:18

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds

Published on: July 16, 2018

8.8K

Perspectives in Engineered Mesenchymal Stem/Stromal Cells Based Anti- Cancer Drug Delivery Systems

Darinka Gjorgieva Ackova, Tatjana Kanjevac, Lia Rimondini

  • 1Faculty of Medical Sciences, University "Goce Delcev" Stip, Krste Misirkov bb, 2000 Stip, R. Macedonia. darko.bosnakovski@ugd.edu.mk.

Recent Patents on Anti-Cancer Drug Discovery
|November 12, 2015
PubMed

Insights

Mesenchymal stem cells (MSCs) can be engineered for targeted cancer therapy, either delivering therapeutic proteins or oncolytic viruses. Their tumor-homing ability makes them promising for novel anti-cancer drug delivery systems.

Area of Science:

  • Biomedical Engineering
  • Oncology
  • Stem Cell Biology

Background:

  • Mesenchymal stem cells (MSCs) exhibit tumor tropism, migrating to tumor sites.
  • Understanding MSCs' dual role in enhancing or inhibiting tumor growth is crucial for cancer research.
  • MSCs offer a platform for developing targeted cancer therapies.

Purpose of the Study:

  • To review current literature and recent patents on MSC-based anti-cancer drug delivery systems.
  • To explore the potential of MSCs in cancer treatment strategies.
  • To present the progress and future prospects of MSCs in anti-cancer drug delivery.

Main Methods:

  • Literature review of current publications.
  • Analysis of recent patents (post-2012) related to MSCs in cancer therapy.
  • Synthesis of findings to outline current progress and future directions.

Main Results:

  • MSCs can be engineered to deliver therapeutic agents directly to tumors.
  • Their inherent tumor-homing properties facilitate targeted drug delivery.
  • Recent patents highlight advancements in MSC-based cancer treatment systems.

Conclusions:

  • MSCs represent a promising platform for developing advanced anti-cancer drug delivery systems.
  • Further research into MSC-tumor interactions can optimize their therapeutic applications.
  • Targeted delivery via MSCs holds potential for improved cancer treatment outcomes.

More Related Videos

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

11.6K
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

9.6K

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
109
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
6.0K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.4K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
109
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
240